Suggested remit: To appraise the clinical and cost effectiveness of teplizumab within its marketing authorisation for delaying the onset of type 1 diabetes in people aged 8 and over at risk of developing the condition.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6259
Provisional Schedule
- Expected publication:
- 08 April 2026
Project Team
- Project lead
- Jen Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Sanofi (Teplizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Breakthrough T1D
- Diabetes UK
- Professional groups
- British Society for Paediatric Endocrinology & Diabetes
- Royal College of Physicians
- UK Clinical Pharmacy Association
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2026 | Committee meeting |
| 10 February 2026 | Declaration of interests |
| 07 October 2025 | Declaration of interests |
| 08 August 2025 - 08 September 2025 | Draft guidance |
| 07 August 2025 | Note - Note added to the project documents |
| 06 May 2025 | Committee meeting |
| 24 September 2024 | Invitation to participate |
| 03 July 2024 - 31 July 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6259 |
| 03 July 2024 | In progress. Scoping commencing |
| 23 February 2024 | Note - Note added to the project documents |
| 14 March 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual